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ABSTRACT
Introduction: The REGAL (RSV Evidence—a
Geographical Archive of the Literature) series
provide a comprehensive review of the
published evidence in the field of respiratory
syncytial virus (RSV) in Western countries over
the last 20 years. This second publication covers
the risk and burden of RSV infection in preterm
infants born at \37 weeks’ gestational age
(wGA) without chronic lung disease or
congenital heart disease.
Methods: A systematic review was undertaken
for articles published between January 1, 1995
and December 31, 2015. Studies reporting data
for hospital visits/admissions for RSV infection
among preterm infants as well as studies
reporting RSV-associated morbidity, mortality,
and risk factors were included. Study quality
and strength of evidence (SOE) were graded
using recognized criteria.
Results: 2469 studies were identified of which
85 were included. Preterm infants, particularly
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those born at lower wGA, tended to have higher
RSV hospitalization (RSVH) rates compared
with otherwise healthy term infants (high
SOE). RSVH rates ranged from *5 per 1000
children to [100 per 1000 children with the
highest rates shown in the lowest gestational
age infants (high SOE). Independent risk factors
associated with RSVH include: proximity of
birth to the RSV season, living with school-age
siblings, smoking of mother during pregnancy
or infant exposure to environmental smoking,
reduced breast feeding, male sex, and familial
atopy (asthma) (high SOE). Predictive models
can identify 32/33–35 wGA infants at risk of
RSVH (high SOE).
Conclusion: RSV infection remains a major
burden on Western healthcare systems and is
associated with significant morbidity. Further
studies focusing on the prevalence and burden
of RSV in different gestational age cohorts, the
changing risk of RSVH during the first year of
life, and on RSV-related mortality in preterm
infants are needed to determine the true burden
of disease.
Funding: AbbVie.
Keywords: Burden; Gestational age;
Hospitalization; Immunoprophylaxis; Preterm;
Respiratory syncytial virus; Risk
INTRODUCTION
Respiratory syncytial virus (RSV) is the most
important cause of severe respiratory infection
in infants, leading to over 3 million
hospitalizations worldwide each year [1]. By
2 years of age, almost all children have been
infected with RSV at least once [2]. Although
the majority of severe cases occur among
previously healthy term infants [3, 4], clinical
studies have shown that infants with a history
of prematurity are at higher risk of RSV
infection requiring hospitalization than
infants born at term [4, 5]. The risks relate to
anatomic factors including small lung volumes,
a reduced lung surface area, small airways, an
increased air space wall thickness, and lower
levels of maternally transmitted antibodies [6].
Although prematurity alone can significantly
increase the risk for severe RSV disease, the
presence of one or more other socioeconomic
and environmental risk factors may also
increase an infant’s susceptibility to severe RSV
disease and subsequent hospitalization [7–12].
Every year, an estimated 15 million infants are
born preterm (before 37 completed weeks of
gestation), and according to the World Health
Organization, this number is rising [13]. In
developed countries, almost 9% of all live births
annually are estimated to be preterm, with
those born between 32 and 37 weeks’
gestational age (wGA) representing the
majority ([80%) of preterm infants [13].
Care of preterm infants with severe RSV
disease places a substantial burden on
pediatric hospital resources each winter [14].
Data from a 2003 retrospective study suggest
that prematurity B35 wGA is a risk factor for
greater use of hospital resources and poorer
clinical outcomes during hospitalization for
severe RSV infection [14]. In addition, RSV
infection in preterm infants has been
associated with chronic respiratory morbidity
and increased healthcare costs [15–19].
Currently, no effective vaccine against RSV
exists, but RSV immunoprophylaxis is
available for certain high-risk groups to
prevent RSV disease. A number of underlying
risk factors that significantly increase the risk of
RSV hospitalization (RSVH) in preterm infants
have been identified [20], most notably from
the Spanish FLIP (Factors that most Likely may
lead to development of RSV related respiratory
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Infection and subsequent hospital admission
among Premature infants born 33–35 wGA)
[7, 8] and the Canadian PICNIC (The Pediatric
Investigators Collaborative Network on
Infections in Canada) [9] studies. Many of
these risk factors have been used to inform
national guidance on the optimal use of RSV
immunoprophylaxis in different countries
including the United States (US) [21], Canada
[22], Spain [23] and Italy [24].
The prevention of RSV in preterm infants,
however, continues to be a challenge. A greater
awareness of the relative importance of
prematurity as a risk factor for severe RSV
disease is essential in order to improve patient
outcomes and reduce the burden on healthcare
systems. To provide a comprehensive
understanding of severe RSV disease in
preterm infants, an expert panel, comprising
Neonatologists, Pediatricians, Pediatric
Infectious Disease Specialists, Pediatric
Cardiologists and Pediatric Pulmonologists
from the US, Canada and Europe, undertook
an evidence-based search of the literature which
has accumulated over the past two decades. The
primary objective of RSV Evidence—a
Geographical Archive of the Literature
(REGAL) was to carry out a series of systematic
reviews and then to assess, quantify, summarize
and grade the evidence base for severe RSV
infection in Western societies. By undertaking
this review, our current understanding of RSV
was defined as well as, importantly, gaps in our
knowledge and future areas of research.
This paper, which represents the second in a
series of seven publications covering a range of
topics on RSV disease, identifies and describes
the risks and associated morbidity and mortality
of severe RSV infection requiring
hospitalization in preterm infants without
chronic lung disease (CLD)/bronchopulmonary
dysplasia (BPD) or congenital heart disease
(CHD) in Western societies.
METHODS
The primary objective of REGAL was to address
seven specific research questions. The
systematic reviews undertaken to answer each
research question all used the same broad
methodology, which has been described
elsewhere [25]. The full protocol and generic
search terms for the systematic reviews are
available as part of the online supplement. In
brief, we conducted a systematic and
comprehensive search of medical literature
electronically indexed in PubMed, EMBASE,
the Cochrane Library, and clinicaltrials.gov.
We used a detailed search strategy and
combined free-text search terms with Medical
Subject Headings. To ensure that the literature
search was manageable, only studies conducted
in Western countries were included, defined as
the US, Canada, and Europe (including Turkey
and the Russian Federation).
The search for this systematic review
included studies conducted in children
(defined as B18 years old) and published
between January 1, 1995 and December 31,
2015. The target population was preterm
infants born at less than 37 wGA without
CLD or CHD (or studies with mixed
populations of healthy preterm infants and
preterm infants, some with comorbidities) who
had ‘proven’ or ‘probable’ RSV and had or had
not received RSV immunoprophylaxis. Other
significant studies of the target population,
published during the drafting of the
manuscript, were also included in the review,
as identified by the authors.
In this systematic literature review, we
sought to answer the two following questions:
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1. What is the predisposition and associated
morbidity, long-term sequelae and
mortality of preterm infants (\37 wGA)
without CLD, BPD or CHD, overall, and
split by gestational age segments, to severe
RSV infection?
2. What are the risk factors associated with
RSVH?
We used the following general terms and limits:
‘‘RSV’’ OR ‘‘respiratory syncytial virus’’ AND
‘‘preterm’’ OR ‘‘premature’’ OR ‘‘gestational
age’’ OR ‘‘gestation’’ AND ‘‘hospitalization’’
AND ‘‘hospitalization’’ OR ‘‘predisposition’’ OR
‘‘risk factor’’ AND ‘‘limits: human, child (birth to
18 years)’’. The search results were
supplemented by review of the bibliographies
of key articles for additional studies and
inclusion of relevant abstracts presented at key
meetings.
The short-term outcomes of interest for this
review included RSVH rates, hospital length of
stay (LOS), intensive care unit (ICU) admission
and LOS, oxygen requirement, need for and
duration of mechanical ventilation and/or
non-invasive ventilation, case-fatality rates,
and risk factors (including biological,
environmental and social) for severe RSV
infection requiring hospital admission.
Evaluation of Data
Included publications were graded according to
the Oxford Centre for Evidence-Based Medicine
Levels of Evidence [26, 27] (Supplementary
Material 1—REGAL Protocol). For each study,
we conducted a risk of bias assessment using the
RTI Item Bank (score of 1 = very high risk of
bias; score of 12 = very low risk of bias) for
observational studies [28]. No quantitative data
synthesis was conducted due to heterogeneity
between studies in terms of design, patient
populations, RSV testing, recording and
availability of outcomes, and differences in
clinical practice between countries and over
time.
Compliance with Ethics Guidelines
The analysis in this article is based on
previously published studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
RESULTS
Articles Selected
From a total of 2469 publications, 85 studies
were included in the final review: 76 identified
from the database searches and a further 9 from
reference lists/other sources (Fig. 1). Data
extraction tables for all 85 studies, including
evidence grades and risk of bias assessments can
be found in the online supplement
(supplementary material 2).
Incidence of RSVH in Preterm Infants
Both prospective and retrospective
population-based studies performed in the US,
Canada and Europe have demonstrated that
infants with a history of prematurity are at
increased risk for RSVH [3–5, 29–46]. Preterm
infants, particularly those born at lower
gestational ages, tended to have higher rates of
hospitalization for RSV compared to otherwise
healthy term infants [4, 5, 31, 37, 43, 47–51]. In
a 5-year prospective, population-based study,
very preterm infants (\30 wGA) accounted for
only 3% of RSV cases, but had RSVH rates three
times that of term infants [4]. In the French
CASTOR (Comparison of the rAte of
hoSpitalization for RSV bronchiolitis between
420 Infect Dis Ther (2016) 5:417–452
preterm infants born at 32 wGA or less without
BPD and full-teRm infants) study, preterm
infants had a fourfold increased risk of
hospitalization for RSV bronchiolitis compared
to the matched full term group (95% confidence
interval [CI]: 1.36–11.80) [50]. In the Dutch
LOLLIPOP (Longitudinal Preterm Outcome
Project) study (ClinicalTrials.gov identifier:
ISRCTN80622320) [43], the rates of RSVH were
found to be higher in preterm infants 32–36
wGA than full term infants (3.9% vs. 1.2%,
relative rate [RR]: 3.2; 95% CI: 1.4–7.1,
P = 0.003), but similar to that among preterm
infants\32 wGA (3.9% vs. 3.2%, RR: 1.2, 95%
CI: 0.7–2.1, P = 0.50) and higher than that
among full term infants. Overall, rates of
RSVH tended to be around 3 times higher in
premature than term infants, albeit with
considerable heterogeneity across studies
(range 1.1–8.1 times higher) [5, 31, 37, 43,
47–51]. In these studies, the majority of preterm
infants were previously healthy, providing
evidence that preterm infants without
underlying conditions, such as CLD (BPD) and
CHD, are at increased risk of developing severe
RSV infection.
RSVH rates for preterm infants over the last
two decades vary in the literature [4, 5, 8–12, 29,
31, 37, 47, 49, 51–57], ranging from *5/1000
children [4] to [100/1000 children [52, 53],
Fig. 1 PRISMA ﬂow diagram: epidemiology and burden of RSV hospitalization in infants born at\37 weeks’ gestational
age without chronic lung disease (bronchopulmonary dysplasia) or congenital heart disease. RSV respiratory syncytial virus
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with the highest RSVH rates reported in the
lowest gestational age infants (Table 1). In the
majority of these studies, RSV
immunoprophylaxis was not given. In the
Dutch RISK [10] and RISK-II [11] studies, the
overall RSVH risk for healthy preterm infants
born at 33–35 wGA was 51/1000 children and
35/1000, respectively. In Austria, the overall
RSVH risk for infants born at 29–32 wGA was
45/1000 children. RSV immunoprophylaxis was
given to 29.7% infants, but almost half of these
received inadequate or incomplete courses [56].
In the PICNIC study [9], the RSVH rate for
infants born at 33–35 wGA was 36/1000
children, although center and seasonal
variation in hospitalization rates for RSV
infection were observed. A more recent study
of 32–35 wGA infants followed prospectively
from September to May 2009–2010 or
2010–2011 in the US [57], found that the
observed hospitalization rate (49/1000
infant-seasons) was similar to that reported in
other studies conducted outside the US that
employed active surveillance for
laboratory-confirmed RSV [9, 44]. In the PONI
study [12], a multinational study (23 countries)
of 33–35 wGA infants B6 months of age during
the October 2013 to April 2014 RSV season, the
RSVH rate was 61/1000 infant-years. Differences
in reported RSVH rates could relate to variability
in study methodology and changes in RSV
testing and/or changes in the use of
RSV-specific codes. These findings highlight
the need for rigorous, uniform and ongoing
data collection.
Chronological age appears to have a strong
effect on RSVH risk in preterm infants [58]. A
retrospective cohort study reported that the risk
of RSVH for a preterm infant born 32–34 wGA
was the same at 4.2–4.5 months of age as for a
term infant at 1 month of age [58]. In a
prospective, population-based study of RSVH in
premature and term infants by Hall et al. [4],
infants B2 months accounted for an important
proportion of all children admitted with RSV
infection in the first 2 years of life: 11% were
infants\1 month old, 44% were B2 months old,
and only 36% were [5 months old. In a
retrospective longitudinal study of 2407
preterm infants in Italy, the incidence of RSVH
declined with age [59]. In this study,
significantly higher incidence rates were
observed in the first 6 months of life and
incidence rates significantly decreased with age
(P\0.01), from 89.3/1000 person-years for
infants aged 0–6 months to 7.6/1000
person-years for infants aged 12–18 months.
Incidence rates also varied significantly by
month of age (P\0.01) and by calendar month
(P\0.01). After 18 months of age, however,
RSVH was rare [59]. A recent retrospective
analysis from the Osservatorio Study in Italy
[60], which enrolled three different gestational
age group infants (\29, 29 to \32 and 32–35
wGA), found that the percentage of hospitalized
preterm infants B12 months old that were RSV
positive progressively decreased from 40.0% to
28.6% and 18.4% with increasing wGA
(P = 0.43). These data suggest that, at least in
the first year of life, the most premature infants
were more vulnerable and prone to RSV
infection [60].
Further data from a post hoc analysis of the
Spanish FLIP 2 study [8] indicate that the risk of
RSV-related hospitalization is maintained in
many preterm infants born at 32–35 wGA up
to at least 6 months old and baseline risk factors
continue to contribute varying risk over the
infants first year of life [61]. These findings may
have implications for future prevention
strategies and the authors suggest that further
prospective studies be undertaken to fully
explore the changing risk of RSVH during the
first year of life in preterm infants [61].
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RSVH Rates by Gestational Age
There is also variability in reported RSVH rates
among different gestational groups, as
evidenced by the results of a large,
population-based Danish study of children
followed from birth to 2 years of age [48]. In
this study, incidence rates of hospitalization for
RSV infection were calculated for five groups of
children separated by gestational age (23–32,
33–35, 36, 37–41, and 42–45 wGA). The highest
hospitalization rates for RSV infection were
found in the group of very preterm children
born 23–32 wGA (50.8/1000 years of risk) [48].
Hall et al. [4] also observed significantly higher
RSVH rates for \30 wGA infants (18.7/1000
children) compared with both 30–33 wGA
infants (2.7/1000 infants) and 34–36 wGA
(5.8/1000 infants). The authors suggest these
variances may primarily result from premature
infants in certain gestational age ranges being
too few to reliably calculate hospitalization
rates by gestational weeks. In addition, care
patterns and environmental risks may be
different for late preterm infants [4]. In
contrast, Cilla et al. [37] found that the
highest RSVH rates in the first year of life were
in infants with a gestational age of 33–35 weeks
(78.1 cases/1000 infants).
Rehospitalization Rates for RSV Infection
Following Discharge from Neonatal ICUs
The reported risk of RSVH for preterm infants
without CLD (BPD) or CHD following discharge
from neonatal ICUs (NICU) ranges from 1.8% to
11.1%, depending on gestational age [62, 63]. In
the study by Joffe et al. [63], three factors
independently increased the risk of
rehospitalization for RSV among preterm
infants who were discharged from the NICU:
\32 wGA, a perinatal oxygen requirement of
C28 days, and discharge from the NICU during
the 3 months before the RSV season. In an
earlier study by Carbonell-Estrany et al. [53],
rehospitalization for a second RSV infection for
a single infant in the same season was observed
during both RSV seasons (11% [1999] and 8%
[2000] of all admissions for RSV illness,
respectively).
Morbidity and Mortality Associated
with Severe RSV Infection
Morbidity
Results from a number of studies show that
preterm infants are at an increased risk for
morbidity and increased rates of health care
resource utilization, including longer duration
of illness and longer hospital stays, compared
with full-term infants [5, 8, 14, 16, 29, 46, 50,
57, 64–72]. Data also show that nosocomial RSV
infection in high-risk infants, including preterm
infants, often follows a severe course of disease
[73].
Children with a history of prematurity are at
a higher risk of worse hospital outcomes (use of
supplemental oxygen, NICU admission) for RSV
infection than term infants [5, 8, 12, 14, 24, 46,
49, 50, 57, 58, 64–72, 74, 75]. In the French
CASTOR study, preterm infants\33 wGA were
prone to more severe disease as suggested by
longer hospital stays and the requirement of
more therapeutic care, including oxygen
therapy and non-mechanical ventilation,
compared with the full-term group [50].
Similarly, a retrospective study conducted in
Central and Eastern Europe (CEE) reported that,
among RSV-positive patients, premature
children (\37 wGA) had a significantly longer
hospital stay (17 vs. 8 days; P\0.001), were
more frequently hospitalized in the ICU (41.4%
vs. 12.6%), and remained in the ICU
significantly longer (13 vs. 6 days; P\0.001)
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compared with term children [46]. In a
Canadian study, Sampalis [64] analyzed data
from 2415 preterm infants (32–35 wGA)
without BPD hospitalized for proven or
probable RSV matched (by GA, gender, and
province of birth) to 20,254 control infants
without RSVH. During hospitalizations after the
index admission, the RSV cohort had a
significantly higher mean number of visits to
special care units (0.67 vs. 0.40, respectively;
P\0.001), use of respiratory therapy (0.31 vs.
0.13, respectively; P\0.001), physician
consults (3.61 vs. 0.89, respectively; P\0.001),
and therapeutic or diagnostic procedures (1.05
vs. 0.81, respectively; P\0.001) compared with
matched control infants. Similar findings were
reported in the United Kingdom (UK) [16].
Shefali-Patel et al. [16] observed that
healthcare utilization was significantly greater
in the RSV compared to the non-respiratory
group for respiratory outpatient visits (6.1 vs.
3.8), hospital admissions (2.3 vs. 0.3; P\0.001),
respiratory-related hospital admission (1.3 vs. 0;
P\0.001), duration of hospital admission (9.6
vs. 0.4 days; P\0.001), pediatric ICU (PICU)
admission (1.6 vs. 0 days; P\0.001), respiratory
primary care visits (12.4 vs. 9.4; P = 0.07),
emergency department visits (3.0 vs. 0.7;
P\0.001), and respiratory emergency
department visits (1.6 vs. 0.1; P\0.001). Data
from a Finnish study also showed that infants
aged \6 months with bronchiolitis were most
likely to need major medical interventions
(supplementary oxygen, intravenous fluids,
intravenous antibiotics or admission to the
ICU) in the first 5 days after disease onset [76].
In contrast to other studies, while admission
to the ICU was associated with a history of
premature birth (odds ratio [OR]: 1.7; 95% CI:
1.1–2.4, P = 0.01), Sala et al. [77] found no
significant difference in the ICU LOS (106
[42–252] days vs. 106 [59–219] days; P = 0.94)
or in mechanical ventilation (OR: 1.1; 95% CI:
0.6–2.1; P = 0.8) between infants with and
without a history of prematurity. Similarly,
Gijtenbeek et al. [43] found no relation
between gestational age and disease severity or
in hospitalization LOS or use of mechanical
ventilation and oxygen.
Further data on hospital resource utilization
for RSV infection in preterm infants without
CLD born at 32–35 wGA and not receiving RSV
immunoprophylaxis come from the REPORT
(RSV Respiratory Events Among Preterm Infants
Outcomes and Risk Tracking) study
(ClinicalTrials.gov identifier: NCT00983606)
[57]. Among the 57 preterm infants with
confirmed hospitalization, the median
duration of hospital stay was 4 days (range
2–18 days); 9 (16%) were admitted to the ICU
and 11% required mechanical ventilation. The
proportion that required ICU admission was
similar among infants born at 32–34 wGA (4 of
21) and 35 wGA (5 of 36) [57]. Additional data
from the REPORT study regarding ICU
admissions suggest that young age is the most
important risk factor associated with the
incidence of ICU admission among 32–35
wGA infants hospitalized for RSV [78]. Among
32–35 wGA infants hospitalized with RSV and
\3 months actual age in weeks since birth, the
proportion admitted to the ICU was 27% (6/22),
and the ICU admission rate was 1.8 per 100
infant-seasons. The highest incidence occurred
at 2 to\3 months actual age. Among those 3 to
\6 months actual age, the proportion admitted
to the ICU was 14% (3/22), yielding a rate of 7
per 1000 infant-seasons. No ICU admissions
occurred in those C6 months [78].
Hospital LOS and healthcare utilization,
including admission to ICU, for preterm
infants \37 wGA are shown in Table 2. This
population at high risk for severe RSV infection
spend a median of 2–17 days in hospital for
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RSV-related illness [14, 16, 24, 31, 50, 57, 79,
80], and up to 75% are admitted to the ICU,
depending on gestational age [12, 14, 16, 46, 50,
57, 72, 74].
In addition to the acute burden placed on
pediatric services during the winter season,
RSVH has been associated with on-going
respiratory morbidity. This will be covered in a
subsequent publication in the REGAL series.
Gestational Age-Specific Complications
and Hospital Resource Use
Severe RSV infection in preterm infants \37
wGA has been shown to result in substantial
morbidity associated with hospitalization, but
few studies have characterized RSV-confirmed
hospitalizations in this high-risk population.
Consistent with previous studies
[5, 14, 49, 57, 58, 65], recently published data
from the ongoing SENTINEL1 study
(ClinicalTrials.gov identifier: NCT02273882)
[74, 81] demonstrated that earlier gestational
age and younger chronologic age were
associated with a higher risk of ICU admission
and need for mechanical ventilation compared
with birth at later gestational age and older
chronologic age (Table 3). In this study, data on
infants born at 29–35 wGA not receiving RSV
immunoprophylaxis were collected from 43
sites across the US [74]. In total, 702 infants
were hospitalized for community-acquired RSV
infection and overall, 42% were admitted to the
ICU and 20% required mechanical ventilation
[74, 81]. Infants\6 months of age accounted for
78% of RSVH observed, 87% of ICU admissions,
and 92% of those requiring mechanical
ventilation [74]. Adjusting for their prevalence
in US births, the number of RSVH among
infants 29–32 and 33–34 wGA were 2-fold
(95% CI: 1.6, 2.4) and 1.5-fold (95% CI: 1.2,
1.8) higher, respectively, than that of infants 35
wGA. The number of ICU admissions among
infants 29–32 and 33–34 wGA were 3.1-fold
(95% CI: 2.2, 4.2) and 1.9-fold (95% CI: 1.4, 2.6)
higher, respectively, than that of infants 35
wGA [81]. The number of mechanical
ventilation events among infants 29–32 and
33–34 wGA were 3.4-fold (95% CI: 2.2, 5.3) and
1.9-fold (95% CI: 1.2, 3.1) higher, respectively,
than that of infants 35 wGA [81]. The
SENTINEL1 study also reported on the costs of
RSVH, which were substantially higher for those
who required greater intensity of care, as
reflected by ICU admission and need for
mechanical ventilation, regardless of wGA and
chronological age [74]. The overall, median cost
per RSVH was $27,461 US dollars [74].
Increasing severity of disease with decreasing
gestational age was also seen in the
retrospective study from CEE [46]. Duration of
hospitalization (mean days, B28 wGA: 29;
29–32 wGA: 24; 33–36 wGA: 11; term: 9), ICU
hospitalization (B28 wGA: 54.3%; 29–32 wGA:
48.8%; 33–36 wGA: 33.8%; term: 14.1%), LOS
in ICU (mean days, B28 wGA: 19; 29–32 wGA:
17; 33–36 wGA: 7; term: 7), supplemental
oxygen use (B28 wGA: 80.0%; 29–32 wGA:
77.9%; 33–36 wGA: 68.3%; term: 47.6%), and
duration of supplementary oxygen use (mean
days, B28 wGA: 19; 29–32 wGA: 12; 33–36 wGA:
5; term: 5) all significantly differed across
gestational age groups (all P\0.001) [46].
Additional data come from a retrospective
cohort study of 684 infants (12.7% preterm
infants B35 wGA) aged B1 year hospitalized for
bronchiolitis or RSV pneumonia over an
18-month period [75]. Preterm infants born at
33–35 wGA had the highest rates of
complications (93%), longest hospital LOS
(7.4 days), and highest costs ($14,137) of all
the gestational groups studied [75].
In addition to the associated morbidity,
RSVH costs for preterm infants have been
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shown to be substantial at follow up
[16–18, 82–84]. In a retrospective cohort study
undertaken in the US, preterm infants born at
33–36 wGA with a RSVH incurred $21,977
higher costs (P\0.001) compared with
corresponding controls without RSVH during
their first year of life [82]. In another
retrospective study in the UK, RSVH was
associated with a significant increase in the
health-related cost of care in the first 2 years
after birth in infants born between 32 and 35
wGA. The mean cost of care in the RSV group
(£12,505) was greater than the non-respiratory
(£1178) (95% CI for difference £5015 to
£17,639, P\0.002) and the other respiratory
(£3356) groups (95% CI for difference £2963 to
£15,606, P\0.001) [16]. It has been calculated
that over the first year of life, 33–36 wGA and
\33 wGA infants hospitalized with RSV go on
to incur healthcare costs almost five times and
three times higher, respectively, than preterm
infants with no history of RSV infection [85]. In
a further study undertaken in the Netherlands,
estimated mean hospitalization costs for RSV
were highest for patients with lower gestational
age (€5555, B28 wGA) as a result of a longer
duration of hospitalization [83]. These findings
highlight the importance of preventive
strategies in this high-risk group.
Case-Fatality Rates
Severe RSV infection is an important cause of
childhood mortality worldwide [1]. However,
few studies in the published literature on RSVH
report case-fatality rates in preterm infants and
therefore it is difficult to ascertain from the
available data the precise number of true RSV
deaths in this high-risk population. Two studies
undertaken in the US [86] and Canada [64] in
the early 2000s reported that RSVH in healthy
premature infants is associated with increased
mortality. Leader et al. [86] found that low birth
weight and/or prematurity (B35 wGA)
independently increased the risk of
post-neonatal RSV-associated death in
children. Case-fatality rates were 43/100,000
for infants without comorbidities born at B35
wGA and weighing \2500 g compared with
20.3/100,000 for infants without comorbidities
born at C37 wGA and weighing\2500 g (total
number of deaths recorded in infants without
comorbidities: 288) [86]. Sampalis [64]
Table 3 Characteristics of community-acquired, respiratory syncytial virus-conﬁrmed hospitalizations in the SENTINEL1
study [74]













Age at admission, monthsa 3 (2–5) 2 (1–4) 2 (1–5) \0.001 \0.01 \0.001
Hospital LOS, daysa 6 (3–12) 6 (3–10) 5 (3–7) NS 0.001 \0.05
ICU admission, n (%) 115 (49) 117 (43) 56 (31) NS \0.001 0.01
ICU LOS, daysa 8 (3–14) 6 (3–12) 5 (3–9) NS NS NS
Mechanical ventilation among all
admissions, n (%)
58 (24) 53 (20) 23 (13) NS \0.01 NS
ICU intensive care unit, IQR interquartile range, LOS length of stay, wGA weeks’ gestational age
a Values reported as median (IQR)
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evaluated morbidity and mortality in healthy
preterm infants (32–25 wGA) and matched
controls and reported an overall mortality rate
during the follow-up period of 8.1% (196/2415)
in the RSV cohort and 1.6% (320/20,254) in the
control infants (OR: 5.5; 95% CI: 4.6–6.6,
P = 0.001). The author concluded that RSVH
in healthy premature infants was associated
with a significant increase in subsequent health
care resource utilization and mortality. More
data are needed on cause of death and how
much is directly attributable to RSV [64].
RSVH and Health-Related Quality of Life
RSV-related hospitalization may cause
significant distress for infants and children
[87], as well as caregivers and families [87, 88].
Leidy et al. [87] performed a prospective study
in 46 RSV-hospitalized infants and children
aged B30 months with a history of
prematurity (B35 wGA) and 45 age-matched
control subjects without RSVH. During
hospitalization, the RSV-infected patients’
health and functional status were significantly
poorer than those of control subjects.
Caregivers of RSV-infected children reported
more stress, greater anxiety, poorer health,
and poorer family health and functioning. As
long as 60 days after hospital discharge,
caregivers of RSV-infected children reported
the children’s health as significantly poorer
and they were personally more anxious,
compared with control subjects [87]. In the
Spanish FLIP-2 study [88], parents of
hospitalized preterm infants of 32–35 wGA
were most likely to have more and longer
times off work for child care (47% vs. 18%), to
have higher work overload, and to obtain lower
values in health-related, quality-of-life
measures.
Independent Gestational Age-Specific Risk
Factors for RSVH
Several important independent risk factors for
RSVH have been identified in preterm infants
who had not received RSV immunoprophylaxis
[48, 50, 52, 53, 55].
23–32 wGA Few studies on risk factors for
RSVH have been performed in extremely
preterm infants. In the study by Haerskjold
et al. [48], the associations between potential
risk factors for hospitalization for RSV infection
were analyzed using a Cox regression model.
Asthma hospitalization before RSV infection
and siblings was associated with increased risk
of hospitalization for RSV infection in children
born between 23 and 32 wGA [48].
29–35 wGA Doering et al. [55] evaluated risk
factors for RSVH in a large German-Austrian
cohort of preterm children with a gestational
age of 29–35 weeks. In multivariate analyses,
four independent risk factors for RSVH were
identified: neurologic problems (OR 3.6); male
sex (OR 2.8); presence of an older sibling (OR
1.7); and discharge from October to December
(OR 1.7). Based on this multivariate analysis,
the estimated risk of RSVH varied between 1%
(no risk factor present) and 30% (4 risk factors
present).
Other studies have analyzed risk factors for
RSVH in infants born at 29–35 wGA
[48, 50, 52, 53]. In two studies undertaken in
Spain, significant independent prognostic
variables for high risk of RSVH in this
gestational group of infants included: lower
gestational age (OR 1.85); chronologic age
\3 months at onset of the RSV season (OR
1.44); CLD (OR 3.1); living with school age
siblings (OR 1.86); and exposure to tobacco
smoke [52, 53]. In the study by Haerskjold et al.
[48], in the adjusted Cox regression model
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chronic disease, asthma hospitalization before
RSV infection, siblings, smoking and day care
were all associated with increased risk of RSVH
in infants born at 33–35 wGA. Similar to other
studies, male gender and the presence of
siblings aged C2 years were independent risk
factors for multiple bronchiolitis
hospitalizations in the French CASTOR study,
which evaluated preterm infants born at \33
wGA without BPD [50].
Breastfeeding, on the other hand, has been
found to have a protective effect [89]. In a
prospective cohort study of 1814 infants born at
B33 wGA, at 12 months of age, the risk of
hospitalization for bronchiolitis was
significantly higher in the ‘never breastfed’
group compared with the ‘breastfed’ group
(hazard ratio: 1.57; 95% CI: 1.00–2.48) [89].
However, data about the specific protective
effect of breastfeeding on RSV in 32/33–35
wGA infants are conflicting [7–9].
32–35 wGA Six large studies have
investigated risk factors in infants born
32/33–35 wGA: the Spanish FLIP [7] and FLIP
2 [8] studies; the Canadian PICNIC [9] study;
the Dutch RISK [10] and RISK-II [11] studies;
and the multinational PONI study [12].
Independent risk factors for RSVH reported in
these studies cover exposure (proximity of birth
to the RSV season, living with school-age
siblings, crowding at home, day care
attendance), social factors (mother smoking
during pregnancy, smoking around infants,
reduced breast feeding), biological factors
(small for gestational age, male sex, familial
wheezing and atopy, young maternal age, low
maternal education), and medical factors
(neonatal respiratory support, short hospital
stay at birth) (Table 4) [7–12]. In addition, a
further analysis using data from several datasets,
including the FLIP study [7] and the FLIP-2
study [8] showed that preterm infants born at
32–35 wGA from smoking families appear to be
at heightened risk for severe RSV infection
requiring hospitalization [90]. In this study,
there were 2.35 times (95% CI 1.37–4.02) as
many hospitalizations amongst infants from
smoking compared with those from
non-smoking families [90].
Several predictive models have been
developed from these six studies, using
between 4 and 7 risk factors, to predict those
premature infants at highest risk of RSVH
[10–12, 91–93] (Table 5). The areas under the
receiver operating characteristic (ROC) curves
ranged from 0.687 to 0.791 for the six models
[10–12, 91–93], representing fair to good
predictive accuracy (0.50–0.75 = fair,
0.75–0.92 = good, 0.92–0.97 = very good, and
0.97–1.00 = excellent) [94]. All the models
except the ones derived from the PONI dataset
[12] have been externally validated
[10, 11, 92, 95–97]. In three of the six models
(FLIP [7], FLIP 2 [8] and PICNIC [10]), age at the
start of the RSV season was the most predictive
variable. In the RISK and RISK-II models
[10, 11], the presence of siblings or the subject
attending day care was the most predictive
variable (age was the second most predictive).
A prospective evaluation of the PICNIC model
found it reduced hospitalization in infants most
‘at-risk’ while avoiding RSV
immunoprophylaxis in a large segment
(81.9%) of 33–35 wGA infants considered at
low risk for RSV infection [98].
Further data on risk factors in this specific
gestational-age group come from the REPORT
study [57]. Consistent with previous
observations in the RISK study [10], overall
RSV disease risk in infants 32–34 and 35 wGA



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Infect Dis Ther (2016) 5:417–452 443
Table 5 Comparison of predictive models for respiratory syncytial virus hospitalization in infants born 32/33–35 wGA
FLIP [91] FLIP 2 [93] PICNIC [92] RISK [10] RISK-II [11] PONI [12]
Risk factors 7












































































































0.791 0.687 0.762 0.703 0.72 0.755
GA gestational age, NR not reported, ROC AUC area under the receiver operating characteristic curve
a ROC curves are constructed by plotting the sensitivity (true positives; number of RSV hospitalized infants predicted to be
hospitalized) against the speciﬁcity (false positives; number of non-hospitalized infants predicted to be RSV hospitalized),
with areas closer to one representing better predictive accuracy
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who were \6 months of age during November
to March and not receiving RSV
immunoprophylaxis was elevated by day care
attendance and preschool-aged,
non-multiple-birth siblings (8.9 and 9.3 per
100 infant-seasons, respectively, vs. 3.5 for all
other infants, P\0.001). Chronologic or
postnatal age\3 months was associated with a
higher RSVH rate for infants 35 wGA but not for
infants 32–34 wGA [57].
32–36 wGA Two further studies have assessed
risk factors for RSVH in 32–36 wGA infants
[43, 99]. In a recent prospective, observational
study of 1825 infants in Ireland who had not
received RSV immunoprophylaxis, 5
independent risk factors for RSVH were
identified [99]. Neonatal respiratory morbidity
(OR: 2.2; 95% CI: 1.28–3.94) or being Caucasian
(OR: 2.3; 95% CI: 1.04–5.29) were
population-specific independent risk factors
for RSVH, whereas the other identified
independent risk factors confirmed those
established in previous studies: older siblings
(OR: 3.8; 95% CI: 1.97–7.41), birth July 15 to
December 15 (OR: 2.1; 95% CI: 1.09–3.92) and
family history of asthma (OR: 1.9; 95% CI:
1.01–3.39) [99]. In a retrospective study in the
Netherlands, shorter gestational age and passive
smoking independently increased the risk for
RSVH among children born at 32–36 wGA, in
multivariable analyses [43].
CONCLUSIONS
The impact of severe RSV infection in high-risk
groups is important in planning preventive
strategies. Findings of this review confirm that
the risk for severe RSV disease is significantly
increased in preterm infants \37 wGA, which
can result in substantial morbidity associated
with hospitalization (Summary Box). In the
majority of these studies, the preterm infants
were previously healthy, providing evidence that
even those without underlying conditions, such
as CLD (BPD) and CHD, are at increased risk of
developing severe RSV infection.
The care of infants with severe RSV disease
places a substantial burden on pediatric hospital
resources and is costly. Although prematurity
alone can significantly increase the risk of severe
RSV disease and subsequent hospitalization,
particularly in the first year of life, the presence
of one or more other socioeconomic and
environmental risk factors may increase an
infant’s susceptibility to RSVH. Gestation-
specific data are important for the planning of
healthcare resource utilization and the use of RSV
prophylactic agents. Further research is therefore
needed on the prevalence and burden of RSV in
different gestational age cohorts. Further
prospective studies should also be undertaken to
fully explore the changing risk of RSVH during the
first year of life in preterm infants.
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Studies have shown that preterm infants, particularly those born at lower gestational
ages, are at high risk for RSVH and tended to have higher rates of hospitalization for
RSV compared with otherwise healthy term infants
1 (Level 1 studies: n = 8; risk of
biasb: 10.9)
RSVH rates for preterm infants ranged from[100 per 1000 children to*5 per 1000,
with the highest rates shown in the lowest gestational age infants
1 (Level 1 studies: n = 8; risk of
biasb: 11.0)
Compared to otherwise healthy/term infants, premature infants have
Longer median hospital stays
Increased complication rates
Increased risk for ICU admission
1 (Level 1 studies: n = 9; risk of
biasb: 10.6)
A number of independent risk factors associated with RSVH in premature infants have
been reported including exposure (e.g. proximity of birth to the RSV season, living
with school-age siblings), social factors (e.g. smoking of mother during pregnancy or
environmental smoking, reduced breast feeding), and biological factors (e.g. male sex,
familial asthma)
1 (Level 1 studies: n = 6; risk of
biasb: 11.0)
Predictive models for RSVH in 32–35 wGA infants have been developed using 4 or 7
risk factors with areas under the ROC curves ranging from 0.687 to 0.791 (fair to
good predictive accuracy)
1 (Level 1 studies: n = 6; risk of
biasb: 11.0)
Key areas for research
In light of the continuing burden and long-term sequelae of severe RSV infection in otherwise healthy preterm infants,
further research is needed on gestation-speciﬁc prevalence and burden of RSV disease to conﬁrm the vulnerability of these
children
Further prospective studies should be undertaken to fully explore the changing risk of RSVH during the ﬁrst year of life in
preterm infants
ICU intensive care unit, ROC receiver operating characteristic, RSV(H) respiratory syncytial virus (hospitalization),
wGA weeks’ gestational age
a Level 1: Local and current random sample surveys (or censuses); Level 2: Systematic review of surveys that allow
matching to local circumstances; Level 3: Local non-random sample; Level 4: Case-series [26, 27]
b Average RTI Item Bank Score [28], where 1 = very high risk of bias and 12 = very low risk of bias
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